1,154 Shares in Stryker Co. (NYSE:SYK) Acquired by 111 Capital

111 Capital acquired a new position in shares of Stryker Co. (NYSE:SYK) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 1,154 shares of the medical technology company’s stock, valued at approximately $415,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of Stryker by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 32,698,828 shares of the medical technology company’s stock worth $11,773,213,000 after purchasing an additional 252,188 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of Stryker by 0.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 11,109,722 shares of the medical technology company’s stock valued at $4,000,056,000 after buying an additional 54,693 shares in the last quarter. FMR LLC lifted its position in shares of Stryker by 10.0% during the 4th quarter. FMR LLC now owns 8,034,844 shares of the medical technology company’s stock valued at $2,892,946,000 after buying an additional 727,850 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Stryker by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 7,073,562 shares of the medical technology company’s stock valued at $2,539,033,000 after buying an additional 168,436 shares in the last quarter. Finally, Norges Bank purchased a new position in shares of Stryker during the 4th quarter valued at approximately $1,710,744,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analysts Set New Price Targets

SYK has been the topic of a number of recent analyst reports. JMP Securities reiterated a “market perform” rating on shares of Stryker in a research report on Monday, May 5th. Citigroup reiterated a “buy” rating and set a $455.00 target price (up previously from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. Needham & Company LLC reiterated a “buy” rating and set a $442.00 target price on shares of Stryker in a research report on Friday, March 21st. Sanford C. Bernstein set a $450.00 target price on Stryker in a research report on Monday, May 5th. Finally, Argus set a $450.00 target price on Stryker in a research report on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and a consensus target price of $427.30.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the sale, the director now directly owns 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. The trade was a 5.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 5.20% of the company’s stock.

Stryker Stock Up 0.5%

NYSE SYK opened at $382.12 on Friday. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The business’s fifty day simple moving average is $368.57 and its 200-day simple moving average is $376.25. The firm has a market cap of $145.85 billion, a PE ratio of 49.24, a P/E/G ratio of 2.93 and a beta of 0.93.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping the consensus estimate of $2.73 by $0.11. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The business had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. During the same quarter in the previous year, the firm earned $2.50 EPS. The company’s quarterly revenue was up 11.9% compared to the same quarter last year. As a group, equities analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Monday, June 30th will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.88%. Stryker’s dividend payout ratio is presently 45.41%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.